Department of Thyroid Surgery, Jinan University First Affiliated Hospital, No. 613 Huangpu Road West, Guangzhou, Guangdong, People's Republic of China.
Department of Dermatology and STD, Jinan University First Affiliated Hospital, Guangzhou, China.
Surg Endosc. 2022 Jun;36(6):4239-4247. doi: 10.1007/s00464-021-08758-7. Epub 2022 Feb 15.
Surgery for thyroid cancer via endoscopic approach was still controversial. Herein, we report the indications, strategies for operative techniques, as well as results for endoscopic central lymph node dissection of thyroid cancer via chest-breast approach (ETCB-CLND).
A retrospective analysis was conducted on the cases of DTC, whom underwent ETCB-CLND from January 2013 to June 2020. Three hundred and twenty-three cases underwent ETCB-CLND (endoscopic group) and 267 cases underwent open surgery (open group). General characteristic, surgical results, thyroglobulin (Tg), radioactive iodine uptake (RAIU), radioactive technetium uptake (RATU), radionuclide imaging of the thyroid residual area (RITRA), and radionuclide imaging of suspicious lymph nodes metastasis (RISLNM) were analyzed and compared between the two groups.
The age of the endoscopic group were lower than that of the open group. The operation time of lobectomy in endoscopic group were longer than that in open group. The gender distribution (P = 0.831), operation time of total thyroidectomy (P = 0.311), intraoperative blood loss (P = 0.672), postoperative hospital stay (P = 0.852), tumor size (P = 0.259), number of cases of lymph node metastasis (P = 0.618), number of dissected lymph nodes (P = 0.681), number of metastatic lymph nodes (P = 0.723), and complications (P = 0.749) did not differ significantly between groups, nor did the surgical range (P = 0.661), Tg at 1 month (P = 0.61) and 1 year (P = 0.67) after surgery, before (P = 0.589) and after (P = 0.593) radioiodine therapy, RAIU-2 h/24 h (P = 0.906/0.582), RATU (P = 0.532), (Tc 15 min:P = 0.503; I 24 h:P = 0.377; I 3d:P = 0.919), RISLNM (none: P = 0.887; central: P = 0.630; lateral: P = 0.659).
The rational and normative application of the endoscopic technique in central lymph node dissection of DTC is safe, feasible, and consistent with the principle of radical tumor cure for selected cases by well-trained surgeons.
经内镜入路进行甲状腺癌手术仍存在争议。在此,我们报告经胸乳入路内镜中央区淋巴结清扫术(ETCB-CLND)治疗甲状腺癌的适应证、手术技术策略以及结果。
回顾性分析 2013 年 1 月至 2020 年 6 月接受 DTC 治疗的患者,其中 323 例行 ETCB-CLND(内镜组),267 例行开放手术(开放组)。分析比较两组患者的一般特征、手术结果、甲状腺球蛋白(Tg)、放射性碘摄取(RAIU)、放射性锝摄取(RATU)、甲状腺残留区放射性碘显像(RITRA)和可疑淋巴结转移放射性碘显像(RISLNM)。
内镜组的年龄低于开放组。内镜组行甲状腺叶切除术的手术时间长于开放组。两组间性别分布(P=0.831)、甲状腺全切除术的手术时间(P=0.311)、术中出血量(P=0.672)、术后住院时间(P=0.852)、肿瘤大小(P=0.259)、淋巴结转移例数(P=0.618)、淋巴结清扫例数(P=0.681)、转移淋巴结例数(P=0.723)和并发症(P=0.749)差异均无统计学意义,手术范围(P=0.661)、术后 1 个月(P=0.61)和 1 年(P=0.67)Tg、碘治疗前(P=0.589)和碘治疗后(P=0.593)、2 h/24 h 放射性碘摄取率(RAIU)(P=0.906/0.582)、RATU(P=0.532)、(Tc15 min:P=0.503;I24 h:P=0.377;I3d:P=0.919)、可疑淋巴结转移(无:P=0.887;中央:P=0.630;侧方:P=0.659)差异亦无统计学意义。
由经验丰富的外科医生进行规范、合理的内镜技术在甲状腺癌中央区淋巴结清扫术中是安全可行的,对选择的病例符合根治性肿瘤治疗原则。